D M Choumerianou1, H Dimitriou1, C Perdikogianni1, G Martimianaki1, M Riminucci1, M Kalmanti1. 1. Department of Pediatric Hematology-Oncology, University Hospital of Heraklion, University of Crete Medical School, Heraklion, Crete, Greece, andDepartment of Experimental Medicine, University of L'Aquila, L'Aquila, Italy.
Abstract
OBJECTIVES: Mesenchymal stromal cells (MSCs) have attracted considerable interest in both the scientific and clinical fields. In order to obtain a sufficient cell number for application, their in vitro expansion is necessary, but during this process their characteristics may be altered and cells may acquire oncogenic properties. We have investigated properties of MSC that may be related to oncogenesis, a critical parameter that has to be evaluated prior to MSC clinical use. MATERIALS AND METHODS: We studied the expression of p53, p16, RB, H-RAS and human telomerase reverse transcriptase (hTERT) in MSCs from bone marrow of children diagnosed with idiopathic thrombocytopenic purpura (ITP) and autoimmune neutropenia. The same cells were seeded in soft agar to confirm their anchorage dependence and were karyotypically analysed. Finally, MSCs were subcutaneously transplanted into SCID mice and their ectopic osteogenic as well as tumorigenic potential was evaluated. RESULTS: We have shown that MSCs derived from bone marrow of children with ITP and autoimmune neutropenia do not undergo transformation, the cells expressed normal levels of p53, p16, RB and H-RAS. Expression of hTERT was undetectable, chromosome content remained stable, and their anchorage dependence was confirmed. In an in vivo model, when MSCs were subcutaneously transplanted into SCID mice, no tumorigenesis was observed. CONCLUSIONS: These findings suggest that MSCs from bone marrow of children do not have oncogenic properties and, therefore, represent validate candidates for applications in regenerative medicine.
OBJECTIVES: Mesenchymal stromal cells (MSCs) have attracted considerable interest in both the scientific and clinical fields. In order to obtain a sufficient cell number for application, their in vitro expansion is necessary, but during this process their characteristics may be altered and cells may acquire oncogenic properties. We have investigated properties of MSC that may be related to oncogenesis, a critical parameter that has to be evaluated prior to MSC clinical use. MATERIALS AND METHODS: We studied the expression of p53, p16, RB, H-RAS and humantelomerase reverse transcriptase (hTERT) in MSCs from bone marrow of children diagnosed with idiopathic thrombocytopenic purpura (ITP) and autoimmune neutropenia. The same cells were seeded in soft agar to confirm their anchorage dependence and were karyotypically analysed. Finally, MSCs were subcutaneously transplanted into SCIDmice and their ectopic osteogenic as well as tumorigenic potential was evaluated. RESULTS: We have shown that MSCs derived from bone marrow of children with ITP and autoimmune neutropenia do not undergo transformation, the cells expressed normal levels of p53, p16, RB and H-RAS. Expression of hTERT was undetectable, chromosome content remained stable, and their anchorage dependence was confirmed. In an in vivo model, when MSCs were subcutaneously transplanted into SCIDmice, no tumorigenesis was observed. CONCLUSIONS: These findings suggest that MSCs from bone marrow of children do not have oncogenic properties and, therefore, represent validate candidates for applications in regenerative medicine.
Authors: J H Ohyashiki; H Hisatomi; K Nagao; S Honda; T Takaku; Y Zhang; G Sashida; K Ohyashiki Journal: Br J Cancer Date: 2005-05-23 Impact factor: 7.640
Authors: Benjamin L Larson; Joni Ylostalo; Ryang H Lee; Carl Gregory; Darwin J Prockop Journal: Tissue Eng Part A Date: 2010-07-13 Impact factor: 3.845
Authors: Spencer W Crowder; Linda W Horton; Sue Hyun Lee; Colt M McClain; Oriana E Hawkins; Amanda M Palmer; Hojae Bae; Ann Richmond; Hak-Joon Sung Journal: FASEB J Date: 2013-04-08 Impact factor: 5.191
Authors: R J Geraghty; A Capes-Davis; J M Davis; J Downward; R I Freshney; I Knezevic; R Lovell-Badge; J R W Masters; J Meredith; G N Stacey; P Thraves; M Vias Journal: Br J Cancer Date: 2014-08-12 Impact factor: 7.640
Authors: P Bossolasco; L Cova; G Levandis; V Diana; S Cerri; G Lambertenghi Deliliers; E Polli; V Silani; F Blandini; M T Armentero Journal: Int J Nanomedicine Date: 2012-01-31